AMEDITECH IMMUTEST MULTI-DRUG SCREEN BUP/PPX/COC150

K063015 · Ameditech, Inc. · DJG · Dec 20, 2006 · Clinical Toxicology

Device Facts

• Record ID: K063015
• Device Name: AMEDITECH IMMUTEST MULTI-DRUG SCREEN BUP/PPX/COC150
• Applicant: Ameditech, Inc.
• Product Code: DJG · Clinical Toxicology
• Decision Date: Dec 20, 2006
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.3650
• Device Class: Class 2

Intended Use

The Ameditech ImmuTest Multi-Drug Screen BUP/PPX/COC150 is an in vitro screen test device for the qualitative detection of multi-drugs in human urine. The cutoff concentrations for this panel test are as follows: Buprenorphine (BUP) 10 ng/ml, Propoxyphene (PPX) 300 ng/ml, Cocaine metabolite (COC150) 150 ng/ml. This test uses multiple test strips in card format (test strips are placed in a card strip holder), cassette format (test strips are placed in a cassette strip holder), and cup format (test strips are placed in a lid strip holder). This test is used to obtain a visual, qualitative result and is intended for professional and laboratory use. This assay provides only a preliminary result. Clinical consideration and professional judgment must be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. In order to obtain a confirmed analytical result, a more specific alternate chemical method is needed. Gas Chromatography/Mass Spectroscopy (GC/MS) is the preferred confirmation method.

Device Story

Device is a lateral flow immunochromatographic test for qualitative detection of buprenorphine, propoxyphene, and cocaine metabolite in human urine; utilizes competitive binding principle. Input is human urine sample; output is visual colored line indicating presence or absence of drug. Used in professional/laboratory settings; operated by healthcare professionals. If drug concentration is below cutoff, antibody-coated particles bind to immobilized drug-specific conjugate, forming a visible line (negative result). If drug is present above cutoff, it saturates antibody binding sites, preventing line formation (positive result). Control line confirms proper sample volume and migration. Results are preliminary; requires GC/MS confirmation for clinical decision-making. Benefits include rapid, point-of-care screening for drug abuse.

Clinical Evidence

No clinical data provided; bench testing only.

Technological Characteristics

Lateral flow immunochromatographic assay; competitive binding principle. Formats: card, cassette, cup with drug-specific test strips (50-59 mm). No electronic components; visually read. Internal control line for sample volume/migration. No specific materials or standards cited.

Indications for Use

Indicated for professional use for the qualitative detection of buprenorphine, propoxyphene, and cocaine metabolites in human urine at specified cutoff concentrations (10 ng/ml, 300 ng/ml, and 150 ng/ml respectively). Provides preliminary analytical test results.

Regulatory Classification

Identification

An opiate test system is a device intended to measure any of the addictive narcotic pain-relieving opiate drugs in blood, serum, urine, gastric contents, and saliva. An opiate is any natural or synthetic drug that has morphine-like pharmocological actions. The opiates include drugs such as morphine, morphine glucoronide, heroin, codeine, nalorphine, and meperedine. Measurements obtained by this device are used in the diagnosis and treatment of opiate use or overdose and in monitoring the levels of opiate administration to ensure appropriate therapy.

Special Controls

*Classification.* Class II (special controls). An opiate test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo for the Department of Health & Human Services - USA. The logo features a stylized eagle with its wings spread, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle. The eagle is black, and the text is in a smaller, lighter font.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

John Wu, Ph.D. Director of Quality Assurance Ameditech, Inc. 10340 Camino Santa Fe, Suite F San Diego, Ca 92121

DEC 2 0 2006

Re: k063015

> Trade/Device Name: Ameditech ImmuTest Multi-Drug Screen BUP/PPX/COC150 Regulation Number: 21 CFR 862.3650 Regulation Name: Enzyme Immunoassay, Opiate test system

Regulatory Class: Class II Product Code: DJG, JXN, DIQ Dated: September 29, 2006 Received: October 3, 2006

Dear Dr. Wu:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device, can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. Mourmust comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing pratise requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

{1}------------------------------------------------

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Alberto Gutierrez, Ph.D.

Alberto Gutierrez, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

## Indications for Use

510(k) Number (if known):

Device Name: Ameditech ImmuTest Multi-Drug Screen BUP/PPX/COC150

Indications For Use:

The Ameditech ImmuTest Multi-Drug Screen BUP/PPX/COC150 is an In Vitro screen test device for the qualitative detection of multi-drugs in human urine. The cutoff concentrations for this panel test are as follows.

| Test | Calibrator | Cutoff (ng/ml) |
|-----------------------------|-----------------|----------------|
| Buprenorphine (BUP) | Buprenorphine | 10 |
| Propoxyphene (PPX) | Propoxyphene | 300 |
| Cocaine metabolite (COC150) | Benzoylecgonine | 150 |

This test uses multiple test strips in card format (test strips are placed in a card strip holder), cassette format (test strips are placed in a cassette strip holder), and cup format (test strips are placed in a lid strip holder).

This test is used to obtain a visual, qualitative result and is intended for professional use.

This assay provides only a preliminary result. Clinical consideration and professional judgment must be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. In order to obtain a confirmed analytical result, a more specific alternate chemical method is needed. Gas Chromatography/Mass Spectroscopy (GC/MS) is the preferred confirmation method.

Prescription Use (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

7

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Carol Benarr
Sign-Off

Page 1 of 1

Sign-Up

of In Vitro Diagnostic Device ation and Safety

K063015